



ASX ANNOUNCEMENT

17 October 2019

## ***Cynata and Sumitomo Dainippon Withdraw from Acquisition Discussions***

**Melbourne, Australia; 17 October 2019:** Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, announces that it has been unable to reach agreement on terms to its satisfaction of a potential acquisition by Sumitomo Dainippon Pharma Co., Ltd ("**Sumitomo**") and accordingly the parties have withdrawn from those discussions.

As announced to ASX on 19 July and 24 July 2019, Cynata received an indicative, non-binding and conditional proposal from Sumitomo on 20 June 2019 regarding a possible acquisition of all of the shares in Cynata at a price of \$2.00 per share in cash by way of a scheme of arrangement.

Cynata continues to progress its Phase 2 clinical trial programs in osteoarthritis and critical limb ischemia, and in graft-versus-host disease with partner Fujifilm, and is actively engaged in commercial discussions with parties interested in partnering with Cynata to develop the Company's unique Cymerus™ therapeutic mesenchymal stem cell (MSC) technology.

**Ends**

**CONTACTS:** Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Claire LaCagnina, U.S. Media Contact, +1 315.765.1462, [clacagnina@6degreespr.com](mailto:clacagnina@6degreespr.com)

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale and without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus™ MSCs into Phase 2 trials for GvHD, critical limb ischemia and osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of asthma, diabetic wounds, heart attack and cytokine release syndrome, a life-threatening condition stemming from cancer immunotherapy.